Show simple item record

dc.contributor.authorVasudev, NS
dc.contributor.authorSelby, PJ
dc.contributor.authorBanks, RE
dc.date.accessioned2018-08-08T09:15:19Z
dc.date.issued2012-09-27
dc.identifier.citationBMC MEDICINE, 2012, 10
dc.identifier.issn1741-7015
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2294
dc.identifier.doi10.1186/1741-7015-10-112
dc.description.abstractSignificant advances in our understanding of the biology of renal cell carcinoma (RCC) have been achieved in recent years. These insights have led to the introduction of novel targeted therapies, revolutionising the management of patients with advanced disease. Nevertheless, there are still no biomarkers in routine clinical use in RCC. Tools used routinely to determine prognosis have not changed over the past decade; classification remains largely morphology based; and patients continue to be exposed to potentially toxic therapy with no indication of the likelihood of response. Thus the need for biomarkers in RCC is urgent. Here, we focus on recent advances in our understanding of the genetics and epigenetics of RCC, and the potential for such knowledge to provide novel markers and therapeutic targets. We highlight on-going research that is likely to deliver further candidate markers as well as generating large, well-annotated sample banks that will facilitate future studies. It is imperative that promising candidates are validated using these resources, and in subsequent prospective clinical trials, so that future biomarkers may be used in the clinic to personalize patient care.
dc.languageeng
dc.language.isoeng
dc.publisherBIOMED CENTRAL LTD
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleRenal cancer biomarkers: the promise of personalized care
dc.typeJournal Article
rioxxterms.versionofrecord10.1186/1741-7015-10-112
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2012-09-27
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBMC MEDICINE
pubs.notesaffiliation: Vasudev, NS (Reprint Author), Inst Canc Res, Fulham Rd, London SW3 6JB, England. Vasudev, Naveen S., Inst Canc Res, London SW3 6JB, England. Selby, Peter J.; Banks, Rosamonde E., St James Univ Hosp, Canc Res UK Ctr, Leeds Inst Mol Med, Leeds, W Yorkshire, England. article-number: 112 keywords: Biomarkers; epigenomics; genomics; renal cell carcinoma; transcriptomics keywords-plus: GENOME-WIDE ASSOCIATION; CPG ISLAND METHYLATION; CELL CARCINOMA; BLADDER-CANCER; KIDNEY CANCER; IDENTIFICATION; GENES; EXPRESSION; SUNITINIB; MARKERS research-areas: General & Internal Medicine web-of-science-categories: Medicine, General & Internal author-email: [email protected] orcid-numbers: Banks, Rosamonde/0000-0002-0042-8715 number-of-cited-references: 61 times-cited: 33 usage-count-last-180-days: 0 usage-count-since-2013: 8 journal-iso: BMC Med. doc-delivery-number: 055CK unique-id: ISI:000312392600003 oa: gold da: 2018-08-08
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Tumour Biology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Tumour Biology
pubs.volume10
pubs.embargo.termsNo embargo
icr.researchteamTumour Biologyen_US
dc.contributor.icrauthorVasudev, Naveenen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0